Drugs induced pulmonary arterial hypertension
Tóm tắt
Từ khóa
Tài liệu tham khảo
Simonneau, 2009, Updated clinical classification of pulmonary hypertension, J Am Coll Cardiol, 54, S43, 10.1016/j.jacc.2009.04.012
Gurtner, 1985, Chronic pulmonary hypertension of vascular etiology, plexogenic pulmonary arteriopathy and the appetite depressant Aminorex: lessons from an epidemic, Swiss Med Wkly, 115, 818
Gurtner, 1985, Aminorex and pulmonary hypertension. A review, Cor et vasa, 27, 160
Simonneau, 1998, Primary pulmonary hypertension associated with the use of fenfluramine derivatives, Chest, 114, 195S, 10.1378/chest.114.3_Supplement.195S
Eddahibi, 2002, Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis, Respir Res, 3, 9, 10.1186/rr181
Eddahibi, 2002, Hyperplasia of pulmonary artery smooth muscle cells is causally related to overexpression of the serotonin transporter in primary pulmonary hypertension, Chest, 121, 97S, 10.1378/chest.121.3_suppl.97S
Eddahibi, 2002, Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension?, J Lab Clin Med, 139, 194, 10.1067/mlc.2002.122181
Herve, 1995, Increased plasma serotonin in primary pulmonary hypertension, Am J Med, 99, 249, 10.1016/S0002-9343(99)80156-9
Loogen, 1985, Long-term follow-up of pulmonary hypertension in patients with and without anorectic drug intake, Cor et vasa, 27, 111
Brenot, 1993, Primary pulmonary hypertension fenfluramine use, Br Heart J, 70, 537, 10.1136/hrt.70.6.537
Abenhaim, 1996, Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group, N Engl J Med, 335, 609, 10.1056/NEJM199608293350901
Souza, 2008, Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases, Eur Respir J, 31, 343, 10.1183/09031936.00104807
Krzentowski, 1979, Effect of benfluorex on the metabolic fate of an oral glucose load in obese subjects with reduced glucose tolerance (author's transl), Therapie, 34, 445
Boutet, 2009, Fenfluramine-like cardiovascular side-effects of benfluorex, Eur Respir J, 33, 684, 10.1183/09031936.00086308
Frachon, 2010, Benfluorex and unexplained valvular heart disease: a case-control study, PloS one, 5, e10128, 10.1371/journal.pone.0010128
Savale, 2012, Pulmonary hypertension associated with benfluorex exposure, Eur Respir J, 40, 1164, 10.1183/09031936.00188611
Schaiberger, 1993, Pulmonary hypertension associated with long-term inhalation of “crank” methamphetamine, Chest, 104, 614, 10.1378/chest.104.2.614
Yakel, 1995, Pulmonary artery hypertension in chronic intravenous cocaine users, Am Heart J, 130, 398, 10.1016/0002-8703(95)90459-X
Collazos, 1996, Acute, reversible pulmonary hypertension associated with cocaine use, Respir Med, 90, 171, 10.1016/S0954-6111(96)90160-2
van Wolferen, 2005, Pulmonary arterial hypertension due to the use of amphetamines as drugs or doping, Nederlands tijdschrift voor geneeskunde, 149, 1283
Chin, 2006, Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?, Chest, 130, 1657, 10.1378/chest.130.6.1657
Tseng, 1998, Expression of a pulmonary endothelial norepinephrine transporter, J Neural Transm, 105, 1187, 10.1007/s007020050121
Salvi, 1999, Alpha1-adrenergic hypothesis for pulmonary hypertension, Chest, 115, 1708, 10.1378/chest.115.6.1708
Marcos, 2004, Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension, Circ Res, 94, 1263, 10.1161/01.RES.0000126847.27660.69
Wellman, 1999, Synergistic interactions between fenfluramine and phentermine, Obes Rev, 23, 723
Rich, 2000, Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension, Chest, 117, 870, 10.1378/chest.117.3.870
Hagiwara, 2000, Delayed onset of pulmonary hypertension associated with an appetite suppressant, mazindol: a case report, Circ J, 64, 218, 10.1253/jcj.64.218
Nittur, 2013, Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review, Sleep Med, 14, 30, 10.1016/j.sleep.2012.07.008
Druker, 2001, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, N Engl J Med, 344, 1031, 10.1056/NEJM200104053441401
Ghofrani, 2010, Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy, Am J Respir Crit Care Med, 182, 1171, 10.1164/rccm.201001-0123OC
Hochhaus, 2007, Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy, Blood, 109, 2303, 10.1182/blood-2006-09-047266
Quintas-Cardama, 2007, Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure, Blood, 109, 497, 10.1182/blood-2006-07-035493
Mattei, 2009, Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient, Bone Marrow Transplan, 43, 967, 10.1038/bmt.2008.415
Rasheed, 2009, Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia, Leuk Res, 33, 861, 10.1016/j.leukres.2008.09.026
Dumitrescu, 2011, Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia, Eur Respir J, 38, 218, 10.1183/09031936.00154210
Montani, 2012, Pulmonary arterial hypertension in patients treated by dasatinib, Circulation, 125, 2128, 10.1161/CIRCULATIONAHA.111.079921
Guignabert, 2013, Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed, Eur Respir J, 41, 3, 10.1183/09031936.00091912
Dusheiko, 1995, Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal, Hepatology, 22, 1863
Tyring, 1995, Interferons: biochemistry and mechanisms of action, Am J Obstet Gynecol, 172, 1350, 10.1016/0002-9378(95)90402-6
Weissmann, 1986, The interferon genes, Prog Nucleic Acid Res Mol Biol, 33, 251, 10.1016/S0079-6603(08)60026-4
Davis, 1989, Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.Hepatitis Interventional Therapy Group, N Engl J Med, 321, 1501, 10.1056/NEJM198911303212203
Brillanti, 1994, A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C, Gastroenterology, 107, 812, 10.1016/0016-5085(94)90131-7
Anderson, 2003, Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies, Am J Hematol, 73, 54, 10.1002/ajh.10319
Dhillon, 2010, Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C, Dig Dis Sci, 55, 1785, 10.1007/s10620-010-1220-7
Hanaoka, 1999, Interferon-alpha elevates pulmonary blood pressure in sheep-the role of thromboxane cascade, Eur J Pharmacol, 370, 145, 10.1016/S0014-2999(99)00107-7
Clerico, 2007, Interferon-beta1a for the treatment of multiple sclerosis, Expert Opin Biol Ther, 7, 535, 10.1517/14712598.7.4.535
Caravita, 2011, Sildenafil therapy for interferon-beta-1a-induced pulmonary arterial hypertension: a case report, Cardiology, 120, 187, 10.1159/000335064
Ledinek, 2009, Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report, Mult Scler, 15, 885, 10.1177/1352458509104593
Tazelaar, 1990, Pulmonary disease associated with l-tryptophan-induced eosinophilic myalgia syndrome. Clinical and pathologic features, Chest, 97, 1032, 10.1378/chest.97.5.1032
Yakovlevitch, 1991, Pulmonary hypertension in a patient with tryptophan-induced eosinophilia-myalgia syndrome, Am J Med, 90, 272, 10.1016/0002-9343(91)80175-L
Hertzman, 1991, The eosinophilia-myalgia syndrome: the Los Alamos Conference, J Rheumatol, 18, 867
Smith, 2005, A heretofore undisclosed crux of eosinophilia-myalgia syndrome: compromised histamine degradation, Inflamm Res, 54, 435, 10.1007/s00011-005-1380-7
Walker, 2006, Temporal trends and drug exposures in pulmonary hypertension: an American experience, Am Heart J, 152, 521, 10.1016/j.ahj.2006.02.020
Barst, 2004, Fatal pulmonary arterial hypertension associated with phenylpropanolamine exposure, Heart, 90, e42, 10.1136/hrt.2004.036491
Van Camp, 2004, Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease, Lancet, 363, 1179, 10.1016/S0140-6736(04)15945-X
Evrard, 2008, Isolated pulmonary hypertension and pergolide, Rev Neurol, 164, 278, 10.1016/j.neurol.2007.09.005
Tiefenbrunn, 1986, Persistent pulmonary hypertension of the newborn, Am Heart J, 111, 564, 10.1016/0002-8703(86)90065-7
Chambers, 2006, Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn, N Engl J Med, 354, 579, 10.1056/NEJMoa052744